| Similar Articles |
|---|
 |
Scientific American
January 2009
Charles Q. Choi |
Do White Blood Cells Make Cancer Deadly? The ability to spread underlies the killing power of cancer. The process occurs, John Pawelek thinks, when tumor cells fuse with white blood cells -- an idea that, if right, could yield new therapies   |
Reactive Reports
Issue 56
Jeffrey Krise |
A Basic Approach to Chemotherapy Chemists have found a way to attack malignant cells with an anticancer drug, while sparing healthy cells. |
Chemistry World
August 19, 2009
Phillip Broadwith |
Antioxidants could promote cancer Some tumor cells can actually use antioxidants to protect themselves from natural cellular defense mechanisms, enabling them to survive and proliferate. |
Scientific American
March 2009
Elaine Schattner |
A Chip against Cancer: Microfluidics Scrutinizes T Cells With just a blood sample, a device could determine whether cancer is about to spread or monitor the progress of treatment |
Chemistry World
July 28, 2009
Michael Gross |
DNA to direct and switch off chemo Researchers in the US have developed a new approach to cancer chemotherapy using short DNA strands to help target delivery of the drug directly to cancer cells, and 'call it off' should problems arise. |
Chemistry World
July 31, 2012
Fiona McKenzie |
Sorting the good from the bad US scientists have found a way to separate cancerous cells from healthy cells by taking advantage of their adhesion properties. Separating cancer cells for analysis is a critical step for determining the recommended course of treatment for patients. |
Chemistry World
March 11, 2010
Simon Hadlington |
Thalidomide Binding Protein Revealed Scientists in Japan believe they have revealed one of the key molecular targets that binds to the drug thalidomide to cause birth defects. |
The Motley Fool
July 24, 2009
Brian Orelli |
Juicing Up the Earnings Report How did Celgene turn an earnings release that met analysts' expectations while lowering revenue guidance on one of its drugs into an 18.6% increase in share price yesterday? |
The Motley Fool
November 20, 2007
Brian Orelli |
Celgene Buys a Sales Force Pharmaceutical Celgene acquires Pharmion for $2.9 billion, hoping that Pharmion's two drugs in mid-to-late clinical trials will justify the purchase price in the not-too-distant future. |
The Motley Fool
August 21, 2008
Brian Lawler |
PDL BioPharma's Partnership Makes Sense Bristol-Myers assumes some of the risk of developing a drug for bone marrow cancer. |
The Motley Fool
January 31, 2008
Brian Lawler |
Prioritizing Millennium The FDA grants a speedy review for Millennium Pharmaceuticals's lead multiple myeloma drug. |
Managed Care
March 2007
Martin Sipkoff |
Managing Cancer Treatment Begins Before Diagnosis Health plans are increasingly involved in promoting the lifestyle changes that help their members avoid cancer, and are increasingly involved in clinical trials if prevention fails. |
AskMen.com
Jacob Franek |
New Cancer Therapies As cancer research explodes, the availability of new and innovative interventions is expanding almost daily. |
The Motley Fool
July 22, 2004
Charly Travers |
A Millennium Pharmaceuticals Mix Sales for one drug are encouraging, while sales for another one are declining. |
Pharmaceutical Executive
December 1, 2005
Ron Feemster |
The PharmExec 2005 Pipeline Report Dry? Not quite. Instead of 1990s-style blockbusters, pharma's new molecules are niche drugs, cancer treatments and -- at last -- innovative mechanisms for troublesome targets: Acomplia [rimonabant] by Sanofi-Aventis... AMG 162 [denosumab] by Amgen... etc. |
The Motley Fool
December 27, 2007
Brian Lawler |
A New Era at Millennium? Millennium Pharmaceuticals submits a supplemental New Drug Application with the FDA to expand the use of lead drug Velcade to patients with multiple myeloma. |
Food Processing
August 2006
Mark Anthony |
Diet and Cancer Over the past 50 years, deaths from heart disease, stroke and infectious diseases have decreased significantly -- but the same cannot be said of cancer. |
Chemistry World
January 2012 |
Column: In the pipeline Derek Lowe discusses how companies are increasingly trying to do more with the compounds they already know a lot about |
Chemistry World
October 2009
Ned Stafford |
The spice of life Many of the world's favourite ingredients have more to offer than just flavor. Many also show health benefits. |
